Abstract
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses cabotegravir (Apretude), 30 mg oral tablets and 200 mg/mL (600 mg/3 mL), extended-release injectable suspension. Indication: For at-risk adults and adolescents aged 12 years and older and weighing at least 35 kg for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call